BMEA · Biomea Fusion, Inc. · Financials
$1.74
+0.04 (+2.35%)
At close · Sep 11
Going-concern doubt
— flagged Aug 5, 2026
Substantial doubt about the company's ability to continue as a going concern.
“In connection with the preparation of this Quarterly Report on Form 10-Q for the period ended June 30, 2026, our management has concluded that there is substantial doubt as to whether we can continue as a going concern for the twelve months following the issuance of this Quarterly Report on Form 10-Q. Our ability to continue as a going concern is dependent upon raising capital to maintain current operations and continue research and development efforts. We plan to raise additional capital to fund our operations through public or private equity offerings, debt financings, and/or potential collaborations and license arrangement or other sources. There is no assurance, however, that any additional financing or any revenue-generating collaboration will be available when needed or that we will be able to obtain financing or enter into a collaboration on terms acceptable to us. Based on our current operating plan, we will not be able to continue as a going concern over the next twelve months unless we raise additional capital by other means. These factors raise substantial doubt about our ability to continue as a going concern.”View the 10-Q filed Aug 5, 2026
Market Cap
$126.12M
Shares
72.48M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Net Income
-$61.8M
+55.4%
FY2025
Diluted EPS
-$1.18
+69.2%
FY2025
Operating Cash Flow
-$70.37M
+41.3%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| $1.85M | $1.86M | $5.64M | $8.88M | — | — | — | — | |
| $40.78M | $61.98M | $118.09M | $102.55M | $62.71M | $28M | $3.67M | $1.09M | |
| $15.08M | $19.33M | $25.99M | $23.59M | $20.92M | $13.67M | $1.66M | $103K | |
| $58.06M | $83.51M | $144.07M | $126.14M | $83.63M | $41.67M | $5.33M | $1.2M | |
| -$58.06M | -$83.51M | -$144.07M | -$126.14M | -$83.63M | -$41.67M | -$5.33M | -$1.2M | |
| — | $0 | $0 | $0 | $0 | $0 | $0 | — | |
| -$32.54M | -$61.8M | -$138.43M | -$117.26M | -$81.83M | -$41.57M | -$5.32M | -$1.2M | |
| -$32.54M | -$61.8M | -$138.43M | -$117.25M | -$81.82M | -$41.58M | -$5.32M | -$1.2M | |
| USD/shares | -$0.16 | -$1.18 | -$3.83 | -$3.44 | -$2.80 | -$1.74 | -$0.51 | — |
| USD/shares | -$0.16 | -$1.18 | -$3.83 | -$3.44 | -$2.80 | -$1.74 | -$0.51 | — |
| shares | — | 52.23M | 36.11M | 34.11M | 29.27M | 23.86M | 10.53M | 6.05M |
| shares | — | 52.23M | 36.11M | 34.11M | 29.27M | 23.86M | 10.53M | 6.05M |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Debt data is being processed. Please check back later.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 5.48×
EV/EBIT
—
Peer median 10.68×
P/E (TTM)
—
Peer median 8.07×
Peer medians compare against the 309 similar-size Biotechnology companies (of 536 listed).
Key facts
CIK
1840439
CUSIP
09077A106
13F (30d)
24 filings
24 filers
Visit website
Investor relations